Johann Colomba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johann Colomba has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
François Tremblay
Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Canada
4 shared publications- Rémi Rabasa-Lhoret
Institut de Recherches Cliniques de Montréal, Montréal, Canada
4 shared publications - Valérie Boudreau
Montreal Clinical Research Institute, Montreal, Quebec, Canada
3 shared publications Adèle Coriati
Montreal Clinical Research Institute (IRCM), Montréal, Québec, Canada
2 shared publications- Anne Bonhoure
Montreal Clinical Research Institute, Montreal, Québec, Canada; Department of Nutrition, Faculty of Medicine, Université de Montréal, Montreal, Québec, Canada
2 shared publications Catherine Lehoux-Dubois
Montreal Clinical Research Institute (IRCM), Montréal, Québec, Canada
2 shared publications
Latest Publications
- 21 September 2021
- Published by Elsevier in Annals of Oncology
- Vol. 32, S1142
1588P SARS-CoV-2 antibody seroprevalence and safety of vaccines in cancer patients who recovered from COVID-19
- 21 September 2021
- Published by Elsevier in Annals of Oncology
- Vol. 32, S1142
1588P SARS-CoV-2 antibody seroprevalence and safety of vaccines in cancer patients who recovered from COVID-19
- 11 March 2021
- Published by Springer Nature in Diabetologia
- Vol. 64 (6) , 1332-1341
Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis
Aims/hypothesis Cystic fibrosis-related diabetes (CFRD) affects up to 50% of adults with cystic fibrosis (CF) and its presence is associated with adverse effects on nutritional status and pulmonary function. Early diagnosis could minimise CFRD morbidity, yet current methods of an OGTT at 0 and 2 h yield unreliable results. Our aim was to determine which indices from a 2 h OGTT with sampling every 30 min might improve prediction of CFRD. Methods Cross-sectional analysis at baseline (n = 293) and observational prospective analysis (n = 185; mean follow-up of 7.5 ± 4.2 years) of the Montreal Cystic Fibrosis Cohort were performed. Blood glucose and insulinaemia OGTT variables were studied in relation to lung function (forced expiratory volume in 1 s [FEV1]), BMI and risk of developing CFRD. Results At baseline, maximum OGTT glucose (Gmax) was negatively associated with FEV1 (p = 0.003). Other OGTT values, including classical 2 h glucose, were not. A higher Gmax was associated with lower insulin secretory capacity, delayed insulin peak timing and greater pancreatic insufficiency (p < 0.01). Gmax was positively associated with the risk of developing CFRD (p = 0.0029); no individual with a Gmax < 8 mmol/l developed CFRD over the following decade. No OGTT variable correlated to the rate of change in BMI or FEV1. Conclusions/interpretation In adults with CF, Gmax is strongly associated with the risk of developing CFRD; Gmax < 8 mmol/l could identify those at very low risk of future CFRD. Gmax is higher in individuals with pancreatic insufficiency and is associated with poorer insulin secretory capacity and pulmonary function. Graphical abstract
- 11 March 2021
- Published by Springer Nature in Diabetologia
- Vol. 64 (6) , 1332-1341
Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis
Aims/hypothesis Cystic fibrosis-related diabetes (CFRD) affects up to 50% of adults with cystic fibrosis (CF) and its presence is associated with adverse effects on nutritional status and pulmonary function. Early diagnosis could minimise CFRD morbidity, yet current methods of an OGTT at 0 and 2 h yield unreliable results. Our aim was to determine which indices from a 2 h OGTT with sampling every 30 min might improve prediction of CFRD. Methods Cross-sectional analysis at baseline (n = 293) and observational prospective analysis (n = 185; mean follow-up of 7.5 ± 4.2 years) of the Montreal Cystic Fibrosis Cohort were performed. Blood glucose and insulinaemia OGTT variables were studied in relation to lung function (forced expiratory volume in 1 s [FEV1]), BMI and risk of developing CFRD. Results At baseline, maximum OGTT glucose (Gmax) was negatively associated with FEV1 (p = 0.003). Other OGTT values, including classical 2 h glucose, were not. A higher Gmax was associated with lower insulin secretory capacity, delayed insulin peak timing and greater pancreatic insufficiency (p < 0.01). Gmax was positively associated with the risk of developing CFRD (p = 0.0029); no individual with a Gmax < 8 mmol/l developed CFRD over the following decade. No OGTT variable correlated to the rate of change in BMI or FEV1. Conclusions/interpretation In adults with CF, Gmax is strongly associated with the risk of developing CFRD; Gmax < 8 mmol/l could identify those at very low risk of future CFRD. Gmax is higher in individuals with pancreatic insufficiency and is associated with poorer insulin secretory capacity and pulmonary function. Graphical abstract
- 1 September 2020
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 19 (5) , 704-711
Dyslipidemia is not associated with the development of glucose intolerance or diabetes in cystic fibrosis
- 1 September 2020
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 19 (5) , 704-711
Dyslipidemia is not associated with the development of glucose intolerance or diabetes in cystic fibrosis
- Open Access
- 18 July 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (7) , e0219855
Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis
Cystic fibrosis (CF) patients are at high risk of developing CF-related diabetes (CFRD). In non-CF patients, liver disease, specifically steatosis and non-alcoholic fatty liver disease (NAFLD), is strongly associated with type 2 diabetes. We compared glycemic status and metabolic profiles in CF patients according to a biomarker of hepatic injury, alanine aminotransferase (ALT). We conducted a cross-sectional study among 273 adult CF patients recruited from the Montreal CF Cohort. A 2-hour oral glucose tolerance test (OGTT) was performed to collect glucose and insulin measures every 30 minutes. Fasting ALT levels and anthropometric measures were also obtained. Patients were categorized into 2 groups based on ALT cut-off of 25 U/L. Patients in the high ALT group were mostly men (83%), had higher mean weight and BMI (pde novo CFRD (20.5% vs 8.2%, p = 0.04) as well as lower insulin sensitivity than men with normal ALT (p = 0.03). ALT levels were strongly associated with HOMA-IR in CFRD patients (p = 0.001, r2 = 0.28). Adult CF men with higher ALT show an increased frequency of dysglycemia and de novo CFRD, lower insulin sensitivity and higher eight. Our data suggests that ALT levels could be an interesting tool to guide targeted diabetes screening, particularly among CF men. Prospective studies are needed to confirm these observations.
- 18 July 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (7) , e0219855
Open AccessHepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis
Cystic fibrosis (CF) patients are at high risk of developing CF-related diabetes (CFRD). In non-CF patients, liver disease, specifically steatosis and non-alcoholic fatty liver disease (NAFLD), is strongly associated with type 2 diabetes. We compared glycemic status and metabolic profiles in CF patients according to a biomarker of hepatic injury, alanine aminotransferase (ALT). We conducted a cross-sectional study among 273 adult CF patients recruited from the Montreal CF Cohort. A 2-hour oral glucose tolerance test (OGTT) was performed to collect glucose and insulin measures every 30 minutes. Fasting ALT levels and anthropometric measures were also obtained. Patients were categorized into 2 groups based on ALT cut-off of 25 U/L. Patients in the high ALT group were mostly men (83%), had higher mean weight and BMI (pde novo CFRD (20.5% vs 8.2%, p = 0.04) as well as lower insulin sensitivity than men with normal ALT (p = 0.03). ALT levels were strongly associated with HOMA-IR in CFRD patients (p = 0.001, r2 = 0.28). Adult CF men with higher ALT show an increased frequency of dysglycemia and de novo CFRD, lower insulin sensitivity and higher eight. Our data suggests that ALT levels could be an interesting tool to guide targeted diabetes screening, particularly among CF men. Prospective studies are needed to confirm these observations.